Finance

Lists
MIST:NASDAQ
Milestone Pharmaceuticals Inc
$0.98
-6.66%
(-0.070) 1D
$1.00
+2.03% (+0.020)
After hours
Closed: Sep 11, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MIST...
Open
$1.06
High
$1.08
Low
$0.98
Mkt. cap
122.02M
Avg. vol.
1.58M
Volume
3.32M
52-wk high
$3.06
52-wk low
$0.98
EPS
-$0.69
Beta
0.98
Shares outstanding
124.50M
No. of employees
38
Open
$1.06
High
$1.08
Low
$0.98
Mkt. cap
122.02M
Avg. vol.
1.58M
Volume
3.32M
52-wk high
$3.06
52-wk low
$0.98
EPS
-$0.69
Beta
0.98
Shares outstanding
124.50M
No. of employees
38
About Milestone Pharmaceuticals Inc
CEO-
Employees38
Founded2003
Headquarters-
SectorPharmaceutical industry
Websitemilestonepharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to MIST in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MIST in the last 3 months.
Highest
Current $0.98
$8.00 (+716.24%)
Average
$6.50 (+563.20%)
Lowest
$3.00 (+206.09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$8.00
+716.2%
09/04/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Initiated
$3.00
+206.1%
08/20/2026
Ritu Baral
TD Cowen
Buy
Maintained
$8.00
+716.2%
08/12/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$7.00
+614.2%
08/13/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$7.00
+614.2%
05/14/2026
Unknown Analyst
Raymond James
Buy
Initiated
$6.00
+512.2%
04/09/2026
Tiago Fauth
Raymond James
Buy
Initiated
$6.00
+512.2%
04/09/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.21 / -$0.19
-9.09%miss
Revenue / Est. (USD)
559.00K / 816.67K
-31.55%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
1.55M
238.00K
559.00K
Cost of goods sold
-
-
14.00K
32.00K
Cost of revenue
-
-
14.00K
32.00K
Research and development expenses
3.94M
5.52M
3.25M
3.51M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.89M
13.28M
20.64M
22.65M
Operating expense
11.83M
18.80M
23.89M
26.16M
Total operating expenses
11.83M
18.80M
23.90M
26.19M
Operating income
-11.83M
-17.26M
-23.66M
-25.63M
Other non operating income
-
-
-
-
EBT including unusual items
-11.92M
-17.41M
-26.07M
-28.61M
EBT excluding unusual items
-11.92M
-17.41M
-26.07M
-28.61M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.92M
-17.41M
-26.07M
-28.61M
Net profit margin
-
-1,126.07%
-10,952.10%
-5,118.78%
Earnings per share
-0.12
-0.15
-0.20
-0.21
Interest and investment income
874.00K
833.00K
1.73M
1.74M
Interest expense
-967.00K
-985.00K
-4.14M
-4.72M
Net interest expenses
-93.00K
-152.00K
-2.40M
-2.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.80M
-17.22M
-23.61M
-25.57M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps